A loss of function of TRPC1, mediated by pharmacological or genetic inhibition, was found to reduce the proliferation of multinucleated glioma cells, mainly due to the suppression of store-operated Ca2+ entry (SOCE) [109]. The gene discussed is TRPC1; the disease is central nervous system cancer.